Alatrofloxacin: Difference between revisions
Appearance
Content deleted Content added
Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEBI_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report errors or bugs) |
Ozzie10aaaa (talk | contribs) m Cleaned up using AutoEd |
||
(31 intermediate revisions by 23 users not shown) | |||
Line 1:
{{Short description|Chemical compound}}
{{ref improve|date=August 2014}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477316351
| IUPAC_name = 7-[(1''R'',5''S'')-6-<nowiki/>{[(2''S'')-1-<nowiki/>{[(2''S'')-
| image = Alatrofloxacin.svg
| width = 250
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|CONS|alatrofloxacin}}
| MedlinePlus = a605016
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
Line 29 ⟶ 32:
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number =
| ATC_prefix = none
| ATC_suffix =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|
| ChemSpiderID =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7QVV6I50DT
Line 44 ⟶ 45:
<!--Chemical data-->
| C=26 | H=25 | F=3 | N=6 | O=5
| smiles =
|
| InChIKey = UUZPPAMZDFLUHD-LZGARRQBBY▼
|
▲| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
}}
'''Alatrofloxacin''' ('''Trovan IV''') is a [[fluoroquinolone antibiotic]] developed by [[Pfizer]], delivered as a [[mesylate]] [[salt (chemistry)|salt]].<ref>{{cite web|title=Center for Drug Evaluation and Research {{ndash}} Application Number: 020759/020760 {{ndash}} Chemistry Review(s)|publisher=[[Food and Drug Administration]]|url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_chemr.pdf|access-date=29 August 2014}}</ref>
[[Trovafloxacin]] and alatrofloxacin were both withdrawn from the U.S. market in June 2006 due to [[hepatotoxicity]] leading to liver transplant or death.<ref>{{cite journal | vauthors = Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL | title = Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 | journal = Pharmacoepidemiology and Drug Safety | volume = 20 | issue = 7 | pages = 772–777 | date = July 2011 | pmid = 21574210 | doi = 10.1002/pds.2155 | s2cid = 23821961 }}</ref>
==
* [[Fluoroquinolones]]
== References ==
{{Reflist}}
{{QuinoloneAntiBiotics}}
Line 69 ⟶ 68:
[[Category:Fluoroquinolone antibiotics]]
[[Category:Prodrugs]]
[[Category:Hepatotoxins]]
[[Category:Withdrawn drugs]]
[[Category:
[[Category:Carboxylic acids]]
{{antibiotic-stub}}▼
▲{{antibiotic-stub}}
|
Latest revision as of 01:55, 31 December 2022
This article needs additional citations for verification. (August 2014) |
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a605016 |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | 76% (trovafloxacin) |
Metabolism | Quickly hydrolyzed to trovafloxacin |
Elimination half-life | 9 to 12 hours (trovafloxacin) |
Excretion | Fecal and renal (trovafloxacin) |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H25F3N6O5 |
Molar mass | 558.518 g·mol−1 |
3D model (JSmol) | |
| |
| |
|
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in June 2006 due to hepatotoxicity leading to liver transplant or death.[2]
See also
[edit]References
[edit]- ^ "Center for Drug Evaluation and Research – Application Number: 020759/020760 – Chemistry Review(s)" (PDF). Food and Drug Administration. Retrieved 29 August 2014.
- ^ Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL (July 2011). "Market withdrawal of new molecular entities approved in the United States from 1980 to 2009". Pharmacoepidemiology and Drug Safety. 20 (7): 772–777. doi:10.1002/pds.2155. PMID 21574210. S2CID 23821961.